Every material Form 8-K Halozyme filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Halozyme's Compensation Committee approved a one-time performance-based restricted stock unit grant to CEO Dr. Helen Torley on December 4, 2025, with a grant date fair value of $10 million. The shares vest only if the company's average share price reaches set levels over a four-year period and Torley remains employed through the fourth anniversary of the grant. The award ties a large part of her pay to sustained share price gains.
Grant approved December 4, 2025 under the 2021 Stock Plan; grant date fair value of $10 million
Vesting ranges from 50% to 200% of target, based on average share price hitting $115, $130, $145 or $170
Shares that become eligible must still vest through the fourth anniversary of the grant date; voluntary resignation or retirement before then forfeits performance-based vested shares
Full award agreement to be filed as an exhibit to the 10-K for fiscal year ending December 31, 2025
Halozyme Therapeutics elected James Lang to its Board of Directors on December 4, 2025, with a term ending at the 2027 annual meeting. He was not initially assigned to any board committee, and the filing states there are no related person transactions or arrangements tied to his election.
James Lang elected to the Board of Directors on December 4, 2025
Term ends at the Company's annual meeting of stockholders in 2027
Not initially assigned to any Board committee
Compensated under the standard non-employee director program, described in the 2025 proxy statement
Halozyme said Chief Financial Officer Nicole LaBrosse will stay in the role until the earliest of a new CFO's hiring, March 30, 2026, or an earlier date the company sets, and then leave for a new professional opportunity. Under a Transition and Release Agreement dated November 18, 2025, she is eligible for severance and equity and benefit treatment tied to a termination without cause, which shareholders can review in the company's 10-K for 2025.
CFO Nicole LaBrosse will serve until the earliest of a new CFO being hired, March 30, 2026, or an earlier date set by the company
Transition and Release Agreement dated November 18, 2025, conditioned on her compliance and a release of claims
Benefits include a 2025 annual bonus at 120% of target and severance equal to base salary, plus a pro-rated 2026 target bonus if she separates in 2026
Health coverage under COBRA paid by the company for one year after the separation date; full agreement to be filed with the 10-K for 2025
Halozyme completed the sale of $1,500.0 million of convertible senior notes due 2031 and 2032, with net proceeds of about $1.47 billion. The company used part of the proceeds to repurchase existing convertible notes for about $1.020 billion in cash and to fund about $182.7 million of capped call transactions, with the remainder for general corporate purposes.
Total principal of $1,500.0 million: $750.0 million of 0% notes due 2031 and $750.0 million of 0.875% notes due 2032, including $100.0 million of each from the initial purchasers' option
Net proceeds of about $1.47 billion; about $1.020 billion paid in cash to repurchase 0.25% notes due 2027 and 1.00% notes due 2028, including accrued interest
Initial conversion price of about $87.20 per share; the 2032 notes pay interest semi-annually at 0.875% beginning May 15, 2026
Halozyme proposed offering $650 million of convertible senior notes due 2031 and $650 million due 2032, with an option for up to $100 million more of each. The company also amended its credit agreement, extending the revolving facility to November 5, 2030 and raising total commitments to $750 million, with $0 currently drawn. The proceeds are partly earmarked for repurchasing existing 2027 and 2028 convertible notes, which adds debt while refinancing part of the existing convertible debt.
Proposed offering: $650 million of 2031 notes and $650 million of 2032 notes, plus a 13-day option for up to $100 million more of each series
Revolving credit facility commitments increased to $750 million and maturity extended to November 5, 2030, with no outstanding borrowings as of November 5, 2025
Net proceeds partly used for capped call transactions and privately negotiated repurchases of 0.25% notes due 2027 and 1.00% notes due 2028
Offering is subject to market conditions and pricing terms were not yet set in the filing
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Halozyme filing is on SEC EDGAR ↗. 8-K briefs of other companies →